Suntory

Last updated January 31, 2026

Innovation Areas

1,494

Inventors

Collaborations

Ergothioneine histamine-n-methyltransferase inhibitors: SuntoryRecent Research Landscape

Neurological and vascular dysfunction stems from unregulated histamine metabolism and oxidative stress, which is mitigated through targeted ergothioneine-driven enzymatic inhibition. This precise biochemical control stabilizes sleep cycles and blood flow to improve therapeutic outcomes.

What technical problems is Suntory addressing in Ergothioneine histamine-n-methyltransferase inhibitors?

Unpleasant organoleptic properties

(16)evidences

The presence of ergothioneine and associated compounds causes offensive bitterness and malodorous off-flavors. Eliminating these sensory barriers is necessary for consumer acceptance of oral formulations.

Impaired neurotransmitter metabolic clearance

(8)evidences

Excessive histamine levels and impaired immune cell energy cycles lead to sleep disturbances and systemic inflammation. Restoring metabolic control over these pathways prevents neurological and immunological dysfunction.

Oxidative discoloration and ingredient instability

(4)evidences

Chemical instability leads to unwanted color changes in oral formulations. Preventing this degradation maintains product integrity and shelf-life.